Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmon... Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology. Mehr anzeigen
Cognizant and Gilead Expand Partnership to Drive Greater Value Through Advanced Technology Applications PR Newswire TEANECK, N.J., Jan. 30, 2025 Cognizant will provide AI-driven solutions to...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 guidance will be released on Tuesday, February 11, 2025, after the...
-- Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral STAT6 Program, Including Targeted Protein Degraders -- -- Gilead...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 4.48 | 4.85058466869 | 92.36 | 96.95 | 92.3577 | 6549883 | 94.50939443 | CS |
| 4 | 4.22 | 4.5562513496 | 92.62 | 96.95 | 88.57 | 6955151 | 92.04603499 | CS |
| 12 | 2.84 | 3.02127659574 | 94 | 98.9 | 86.08 | 7131973 | 92.20090725 | CS |
| 26 | 19.42 | 25.0839576337 | 77.42 | 98.9 | 72.43 | 6570157 | 86.81536863 | CS |
| 52 | 18.04 | 22.8934010152 | 78.8 | 98.9 | 62.07 | 6987915 | 77.97323628 | CS |
| 156 | 28.2 | 41.0839160839 | 68.64 | 98.9 | 57.165 | 7090663 | 74.27780983 | CS |
| 260 | 32.94 | 51.5492957746 | 63.9 | 98.9 | 56.56 | 8401894 | 72.10801511 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
